Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for ANAB

Stock NameAnaptysBio Inc
TickerANAB(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0327241065
LEI529900HH4WQT03IG1A12

Show aggregate ANAB holdings

News associated with ANAB

AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $45.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 127.16% from the company’s current price. Several other […] - 2025-09-18 02:24:44
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.13
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy […] - 2025-09-16 02:46:48
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.13 Average Target Price from Analysts
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to […] - 2025-08-22 03:12:54
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group
UBS Group restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock, up from their prior price target of $18.00. A number of other research analysts have also […] - 2025-08-13 04:26:45
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)
Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 24.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,062 shares of the biotechnology company’s stock after selling 660 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-11 05:32:56
Federated Hermes Inc. Has $154,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)
Federated Hermes Inc. lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,274 shares of the biotechnology company’s stock after selling 36,910 shares during the quarter. Federated Hermes Inc.’s holdings […] - 2025-08-11 04:48:58
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The […] - 2025-07-30 04:24:54
Alps Advisors Inc. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)
Alps Advisors Inc. trimmed its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,126 shares of the biotechnology company’s stock after selling 1,478 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:26:00
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $42.38
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-07-03 02:41:00
AnaptysBio (NASDAQ:ANAB) Upgraded at HC Wainwright
AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock, up from their previous price objective of $22.00. HC Wainwright’s […] - 2025-06-06 02:58:51
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Squarepoint Ops LLC
Squarepoint Ops LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,870 shares of the biotechnology company’s stock after purchasing an additional 36,365 shares during the period. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $1,071,000 as of its most recent filing […] - 2025-06-01 05:29:02
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $90.00 target price on the biotechnology company’s stock, up from their previous target price of $54.00. Guggenheim’s price objective points to a […] - 2025-05-30 03:08:51
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $52.00 to $54.00. The stock had previously closed at $20.13, but opened at $21.14. Guggenheim currently has a buy rating on the stock. AnaptysBio shares last traded at $22.10, […] - 2025-05-30 02:27:21
D. E. Shaw & Co. Inc. Reduces Stake in AnaptysBio, Inc. (NASDAQ:ANAB)
D. E. Shaw & Co. Inc. trimmed its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 197,107 shares of the biotechnology company’s stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc.’s holdings in AnaptysBio were worth $2,610,000 as […] - 2025-05-20 04:57:05
18,954 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Bought by Graham Capital Management L.P.
Graham Capital Management L.P. bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 18,954 shares of the biotechnology company’s stock, valued at approximately $251,000. Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased […] - 2025-05-19 05:26:52
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.88
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-05-14 02:34:53
Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB)
Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 05:26:54
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 05:18:48
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.
Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 04:22:49
Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO)
AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 03:56:46
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 03:52:42
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 04:10:52
AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 06:31:49
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 04:26:55
Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)
Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 07:55:30
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)
AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 04:36:55
Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB)
Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 07:10:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ANAB holdings

DateNumber of ANAB Shares HeldBase Market Value of ANAB SharesLocal Market Value of ANAB SharesChange in ANAB Shares HeldChange in ANAB Base ValueCurrent Price per ANAB Share HeldPrevious Price per ANAB Share Held
2025-11-12 (Wednesday)6,055ANAB holding decreased by -19USD 200,360ANAB holding decreased by -3483USD 200,360-19USD -3,483 USD 33.09 USD 33.5599
2025-11-11 (Tuesday)6,074USD 203,843ANAB holding decreased by -2552USD 203,8430USD -2,552 USD 33.5599 USD 33.9801
2025-11-10 (Monday)6,074USD 206,395ANAB holding decreased by -34439USD 206,3950USD -34,439 USD 33.9801 USD 39.65
2025-11-07 (Friday)6,074USD 240,834ANAB holding increased by 8807USD 240,8340USD 8,807 USD 39.65 USD 38.2
2025-11-06 (Thursday)6,074ANAB holding decreased by -19USD 232,027ANAB holding increased by 12679USD 232,027-19USD 12,679 USD 38.2 USD 36
2025-11-05 (Wednesday)6,093ANAB holding decreased by -190USD 219,348ANAB holding increased by 1077USD 219,348-190USD 1,077 USD 36 USD 34.7399
2025-11-04 (Tuesday)6,283ANAB holding decreased by -38USD 218,271ANAB holding decreased by -9538USD 218,271-38USD -9,538 USD 34.7399 USD 36.04
2025-11-03 (Monday)6,321ANAB holding decreased by -38USD 227,809ANAB holding decreased by -4803USD 227,809-38USD -4,803 USD 36.04 USD 36.58
2025-10-31 (Friday)6,359USD 232,612ANAB holding increased by 699USD 232,6120USD 699 USD 36.58 USD 36.47
2025-10-30 (Thursday)6,359USD 231,913ANAB holding increased by 2226USD 231,9130USD 2,226 USD 36.47 USD 36.12
2025-10-29 (Wednesday)6,359USD 229,687ANAB holding decreased by -254USD 229,6870USD -254 USD 36.12 USD 36.1599
2025-10-28 (Tuesday)6,359ANAB holding increased by 57USD 229,941ANAB holding increased by 1935USD 229,94157USD 1,935 USD 36.1599 USD 36.1799
2025-10-27 (Monday)6,302USD 228,006ANAB holding increased by 6995USD 228,0060USD 6,995 USD 36.1799 USD 35.07
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANAB by Blackrock for IE00B3VWM098

Show aggregate share trades of ANAB

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-1934.30032.925 33.062USD -628 22.74 Loss of -196 on sale
2025-11-06SELL-1940.96035.910 36.415USD -692 22.45 Loss of -265 on sale
2025-11-05SELL-19039.78034.220 34.776USD -6,607 22.38 Loss of -2,355 on sale
2025-11-04SELL-3836.50034.595 34.786USD -1,322 22.32 Loss of -474 on sale
2025-11-03SELL-3837.12035.535 35.693USD -1,356 22.25 Loss of -511 on sale
2025-10-28BUY5736.16037.000 36.916USD 2,104 21.94
2025-10-24SELL-1935.07035.145 35.138USD -668 21.79 Loss of -254 on sale
2025-10-15BUY11434.29034.415 34.403USD 3,922 21.30
2025-10-02BUY1931.34032.150 32.069USD 609 21.19
2025-10-01BUY3831.97033.480 33.329USD 1,267 21.12
2025-09-11BUY7623.20023.635 23.592USD 1,793 21.03
2025-08-21SELL-320.36020.570 20.549USD -62 21.03 Profit of 1 on sale
2025-07-31BUY924.55025.255 25.184USD 227 21.02
2025-06-30SELL-622.20022.830 22.767USD -137 20.47 Loss of -14 on sale
2025-06-25SELL-323.24023.590 23.555USD -71 20.42 Loss of -9 on sale
2025-06-20SELL-623.17023.450 23.422USD -141 20.36 Loss of -18 on sale
2025-05-30SELL-4,50522.23022.590 22.554USD -101,606 20.03 Loss of -11,349 on sale
2025-05-23BUY1820.44020.750 20.719USD 373 20.00
2025-05-19SELL-1820.47020.730 20.704USD -373 19.97 Loss of -13 on sale
2025-05-15SELL-5420.40020.790 20.751USD -1,121 19.97 Loss of -42 on sale
2025-05-12SELL-1820.03021.140 21.029USD -379 19.97 Loss of -19 on sale
2025-05-09SELL-1819.59020.040 19.995USD -360 19.97 Loss of 0 on sale
2025-04-30SELL-1822.22022.515 22.485USD -405 19.92 Loss of -46 on sale
2025-04-24SELL-3620.61020.680 20.673USD -744 19.87 Loss of -29 on sale
2025-04-17SELL-1820.55020.750 20.730USD -373 19.83 Loss of -16 on sale
2025-04-15SELL-5418.10018.650 18.595USD -1,004 19.85 Profit of 68 on sale
2025-04-14SELL-5417.86018.090 18.067USD -976 19.88 Profit of 98 on sale
2025-04-09SELL-7216.90018.130 18.007USD -1,297 19.98 Profit of 142 on sale
2025-04-07SELL-12617.78018.740 18.644USD -2,349 20.04 Profit of 176 on sale
2025-04-04SELL-18018.51019.360 19.275USD -3,470 20.06 Profit of 141 on sale
2025-03-31BUY1818.59018.805 18.784USD 338 20.11
2025-03-19SELL-3616.44016.540 16.530USD -595 20.34 Profit of 137 on sale
2025-03-14SELL-10816.73017.730 17.630USD -1,904 20.50 Profit of 310 on sale
2025-03-13SELL-3616.84018.080 17.956USD -646 20.56 Profit of 94 on sale
2025-03-12SELL-61217.71018.500 18.421USD -11,274 20.60 Profit of 1,332 on sale
2025-03-07SELL-3616.34017.205 17.118USD -616 20.77 Profit of 131 on sale
2025-03-06SELL-5416.40016.790 16.751USD -905 20.83 Profit of 221 on sale
2025-03-03SELL-1814.64017.260 16.998USD -306 21.09 Profit of 74 on sale
2025-02-28SELL-29,30216.82019.450 19.187USD -562,217 21.16 Profit of 57,830 on sale
2025-02-26SELL-9517.00017.760 17.684USD -1,680 21.31 Profit of 345 on sale
2025-02-25SELL-28817.19017.600 17.559USD -5,057 21.38 Profit of 1,101 on sale
2025-02-18BUY47519.78021.570 21.391USD 10,161 21.63
2025-02-13BUY19019.29019.360 19.353USD 3,677 21.69
2025-02-11BUY28512.37512.990 12.928USD 3,685 22.00
2025-02-06BUY85516.08016.180 16.170USD 13,825 22.49
2025-01-27BUY9517.46017.730 17.703USD 1,682 23.64
2024-12-30BUY47513.22013.340 13.328USD 6,331 24.69
2024-12-06BUY38024.81024.950 24.936USD 9,476 24.80
2024-12-05BUY9523.66025.470 25.289USD 2,402 24.84
2024-12-04BUY47524.08024.700 24.638USD 11,703 24.86
2024-11-29BUY47524.96025.680 25.608USD 12,164 24.99
2024-11-27BUY38025.12026.510 26.371USD 10,021 24.98
2024-11-26BUY9525.25025.320 25.313USD 2,405 24.97
2024-11-25BUY9,82124.10025.110 25.009USD 245,613 25.01
2024-11-21BUY32521.17021.640 21.593USD 7,018 25.36
2024-11-20BUY19520.31020.590 20.562USD 4,010 25.64
2024-11-18BUY78018.88019.240 19.204USD 14,979 26.41
2024-11-12BUY52021.50022.805 22.675USD 11,791 26.74
2024-11-08BUY32521.31021.805 21.756USD 7,071 27.13
2024-11-07BUY97521.49022.620 22.507USD 21,944 27.56
2024-11-06BUY13022.21022.950 22.876USD 2,974 28.01
2024-10-31BUY6521.63022.475 22.391USD 1,455 31.62
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANAB

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1992,3080183,00550.4%
2025-09-1858,2010106,68754.6%
2025-09-17105,431873320,51432.9%
2025-09-16191,35114,369566,48033.8%
2025-09-15166,54212,680469,72935.5%
2025-09-12122,6190188,38265.1%
2025-09-11107,5890138,67177.6%
2025-09-10122,3850174,86370.0%
2025-09-0969,966098,95770.7%
2025-09-0874,7340107,41769.6%
2025-09-0575,3290104,69871.9%
2025-09-04113,2190168,71667.1%
2025-09-03102,1330140,37872.8%
2025-09-0229,71412245,20865.7%
2025-08-29105,6780137,68576.8%
2025-08-2818,607046,58939.9%
2025-08-2747,64887076,47962.3%
2025-08-2648,0801,00099,55348.3%
2025-08-2535,311052,98966.6%
2025-08-2254,26232878,72268.9%
2025-08-2183,0952,019146,96856.5%
2025-08-2058,2020101,83957.2%
2025-08-1969,3490109,09563.6%
2025-08-1845,75730066,87268.4%
2025-08-1549,379085,03058.1%
2025-08-1451,063193,19554.8%
2025-08-13176,60866417,78742.3%
2025-08-1248,149098,55648.9%
2025-08-1170,0020155,36045.1%
2025-08-08139,05821,803613,21022.7%
2025-08-0779,784643173,81145.9%
2025-08-0677,5213179,67743.1%
2025-08-0565,1670161,07040.5%
2025-08-0427,989067,30341.6%
2025-08-0145,1550116,70338.7%
2025-07-3184,525960201,92041.9%
2025-07-30155,697816333,90046.6%
2025-07-2957,49560119,68548.0%
2025-07-2859,0230119,58149.4%
2025-07-2573,69249186,89339.4%
2025-07-2470,23854146,16648.1%
2025-07-2392,5771,556353,30726.2%
2025-07-2255,8414,032156,45735.7%
2025-07-21102,03040188,90654.0%
2025-07-1850,078980,37462.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.